Insights from transgenic mouse models of ERBB2-induced breast cancer
暂无分享,去创建一个
Robert D. Cardiff | R. Cardiff | J. Ursini-Siegel | W. Muller | Josie Ursini-Siegel | William J. Muller | Babette Schade | Babette Schade | Josie Ursini-Siegel
[1] B. Kennedy,et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis , 2007, Nature Genetics.
[2] Mitchell D Schnall,et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.
[3] R. Cardiff,et al. Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.
[4] Y. Ho,et al. Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines 1 , 2003, The Journal of Immunology.
[5] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[6] Dana M. Brantley-Sieders,et al. Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.
[7] P. Triozzi,et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.
[8] S. Sukumar,et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. , 2001, Oncogene.
[9] M. Barcellos-Hoff,et al. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression , 2006, Oncogene.
[10] N. Kenney,et al. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E , 2002, Oncogene.
[11] S. Kingsmore,et al. Genetic mapping of the mouse topoisomerase IIα gene to Chromosome 11 , 2004, Mammalian Genome.
[12] P. Leder,et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.
[13] Tiansen Li,et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.
[14] C. Hudis,et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. , 2002, Cancer research.
[15] Robert D Cardiff,et al. The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.
[16] V. Durbecq,et al. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. , 2007, Cancer treatment reviews.
[17] Jeffrey M. Skerker,et al. in Human Breast Cancer Cell Lines , 1994 .
[18] D. Slamon. Studies of the HER-2/neu proto-oncogene in human breast cancer. , 1990, Cancer investigation.
[19] R. Cardiff,et al. Angiogenic Acceleration of Neu Induced Mammary Tumor Progression and Metastasis , 2004, Cancer Research.
[20] R. Weinberg,et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.
[21] François Vaillant,et al. Generation of a functional mammary gland from a single stem cell , 2006, Nature.
[22] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[23] M. Lisanti,et al. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. , 2006, Cancer research.
[24] M. Moran,et al. Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.
[25] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Sukumar,et al. Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.
[27] Robert D Cardiff,et al. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. , 2002, The American journal of pathology.
[28] L. Hennighausen,et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice , 2001, Transgenic Research.
[29] B. Li,et al. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice , 1997, Molecular and cellular biology.
[30] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[31] M. Pegram,et al. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. , 2006, Advanced drug delivery reviews.
[32] R. Cardiff,et al. Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.
[33] Päivikki Kauraniemi,et al. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.
[34] P. Jolicoeur,et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.
[35] Priti Garg,et al. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.
[36] P. D’Eustachio,et al. The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.
[37] I. Bièche,et al. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. , 1994, Cancer research.
[38] P. Canney,et al. A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. , 2006, European journal of cancer.
[39] Irene L Andrulis,et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.
[40] Kuala Lumpur Malaysia,et al. Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.
[41] P. Leder,et al. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.
[42] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[43] R. Hynes,et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] Robert D Cardiff,et al. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.
[45] C. Hauser,et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. , 2005, Cancer research.
[46] H. Varmus,et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] J. Gray,et al. Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. , 2005, Cancer research.
[48] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[49] N. Robert,et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] W. Muller,et al. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.
[51] H. Koeppen,et al. HER 2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER 2-Transgenic Mice , 2004 .
[52] A. Olshen,et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[53] G. Dontu,et al. Stem cells in mammary development and carcinogenesis , 2007, Stem Cell Reviews.
[54] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[55] L. Donehower,et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.
[56] C. Hudis,et al. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments , 2004, Clinical Cancer Research.
[57] R. Cardiff,et al. The Comparative Pathology of Human and Mouse Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.
[58] R. Cardiff,et al. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[59] G. Inghirami,et al. β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis , 2006, Cell.
[60] G. McKnight,et al. The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. , 1988, Molecular endocrinology.
[61] Makoto Katsumata,et al. Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.
[62] F. Révillion,et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells , 2001 .
[63] P. Musiani,et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[64] W. Muller,et al. Oncogenic Activating Mutations in the neu/erbB‐2 Oncogene Are Involved in the Induction of Mammary Tumors , 1999, Annals of the New York Academy of Sciences.
[65] T. Pandita,et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] G. Hortobagyi. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. , 2001, Seminars in oncology.
[67] M. Moran,et al. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.
[68] N. Lemoine,et al. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. , 1990, Oncogene.
[69] H. Hermeking. The 14-3-3 cancer connection , 2003, Nature Reviews Cancer.
[70] R. Cardiff,et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. , 2005, Cancer research.
[71] Å. Borg,et al. Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis , 1992 .
[72] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[73] H. Koeppen,et al. HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice , 2004, Clinical Cancer Research.
[74] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[75] M. Hung,et al. A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.
[76] W. Muller,et al. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[77] S. Rane,et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. , 2005, Cancer research.
[78] Å. Borg,et al. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. , 1992, Genes, chromosomes & cancer.
[79] M. Rudnicki,et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[80] J. Berzofsky,et al. Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice , 2004, Cancer Research.
[81] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[82] Max S Wicha,et al. Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.
[83] R. Cardiff,et al. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. , 2003, Cancer research.
[84] B. Groner,et al. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice , 1993, The Journal of cell biology.
[85] R. Weinberg,et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.
[86] T. Ried,et al. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu , 2002, Oncogene.
[87] Stefan Handt,et al. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization , 2001, The Journal of pathology.
[88] W. Muller,et al. Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins* , 2001, The Journal of Biological Chemistry.
[89] E. Lander,et al. Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[90] A. Sapino,et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. , 2006, Cancer research.
[91] A. Toker,et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.
[92] E. Schröck,et al. A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV‐cmyc transgenic mice , 1999, Genes, chromosomes & cancer.